Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for XENE
| Stock Name | Xenon Pharmaceuticals Inc |
| Ticker | XENE(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | CA98420N1050 |
Show aggregate XENE holdings
News associated with XENE
- Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders bought 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the average volume of 165 put options. Institutional Trading of Xenon Pharmaceuticals Institutional investors have recently modified their holdings […] - 2025-09-18 04:48:00
- Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors purchased 4,063 put options on the company. Thisrepresentsanincreaseofapproximately2,362% compared to the typical volume of 165 put options. Analyst Ratings Changes A number of analysts have weighed in on the stock. Wall Street Zen downgraded […] - 2025-08-22 02:22:44
- Royal Bank Of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price
- Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target decreased by analysts at Royal Bank Of Canada from $57.00 to $55.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target indicates a potential upside of 46.00% […] - 2025-08-14 02:13:05
- Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Wedbush Analyst Says
- Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target upped by stock analysts at Wedbush from $42.00 to $43.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Wedbush’s target price indicates a potential upside of 14.15% from […] - 2025-08-14 02:13:01
- Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up on Analyst Upgrade
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) shares gapped up before the market opened on Tuesday after Wedbush raised their price target on the stock from $42.00 to $43.00. The stock had previously closed at $34.11, but opened at $36.00. Wedbush currently has an outperform rating on the stock. Xenon Pharmaceuticals shares last traded […] - 2025-08-13 02:36:44
- 11,949 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Y Intercept Hong Kong Ltd
- Y Intercept Hong Kong Ltd bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,949 shares of the biopharmaceutical company’s stock, valued at approximately $401,000. Other large investors […] - 2025-07-29 05:16:54
- Investors Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) saw unusually large options trading on Wednesday. Traders acquired 4,063 put options on the company. This is an increase of 2,362% compared to the average daily volume of 165 put options. Institutional Inflows and Outflows Large investors have recently made changes to their positions in the stock. […] - 2025-07-24 04:56:56
- New York State Common Retirement Fund Buys 9,851 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
- New York State Common Retirement Fund lifted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 7.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 142,372 shares of the biopharmaceutical company’s stock after acquiring an additional 9,851 […] - 2025-07-22 07:10:51
- Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) saw unusually large options trading on Wednesday. Traders bought 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Hedge Funds Weigh In On Xenon Pharmaceuticals Several large investors have recently modified their holdings of […] - 2025-06-26 03:00:54
- Comparing Xenon Pharmaceuticals (NASDAQ:XENE) & Inhibitor Therapeutics (OTCMKTS:INTI)
- Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and Inhibitor Therapeutics (OTCMKTS:INTI – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation. Insider & Institutional Ownership 95.4% of Xenon Pharmaceuticals […] - 2025-06-04 03:06:45
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of “Buy” from Brokerages
- Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) have earned an average recommendation of “Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. Twelve equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage […] - 2025-05-26 04:40:52
- Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com
- Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday. Other equities research analysts have also issued reports about the stock. Evercore ISI assumed coverage on shares of Xenon Pharmaceuticals in a research note […] - 2025-05-21 05:12:51
- D. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
- D. E. Shaw & Co. Inc. lowered its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 57.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,973 shares of the biopharmaceutical company’s stock after selling 117,919 shares during the quarter. D. […] - 2025-05-19 05:12:55
- Xenon Pharmaceuticals (NASDAQ:XENE) Given New $47.00 Price Target at Wells Fargo & Company
- Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its target price cut by Wells Fargo & Company from $50.00 to $47.00 in a research report report published on Tuesday, Marketbeat.com reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other research analysts also recently issued reports on the company. William Blair reaffirmed […] - 2025-05-16 03:05:00
- Needham & Company LLC Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00
- Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price target trimmed by Needham & Company LLC from $60.00 to $55.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on XENE. The Goldman Sachs […] - 2025-05-16 03:04:59
- Chardan Capital Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
- Chardan Capital reaffirmed their buy rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $55.00 price objective on the biopharmaceutical company’s stock. Several other research firms also recently commented on XENE. Royal Bank of Canada reiterated an “outperform” rating on shares of […] - 2025-05-16 03:04:56
- Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock investors purchased 4,063 put options on the stock. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Analysts Set New Price Targets Several research analysts recently issued reports […] - 2025-05-15 04:31:06
- Royal Bank of Canada Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price
- Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target reduced by equities research analysts at Royal Bank of Canada from $58.00 to $55.00 in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target […] - 2025-05-15 02:48:49
- HC Wainwright Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
- Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $53.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 78.21% from the stock’s previous close. Other research analysts […] - 2025-05-15 02:48:48
- StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to “Hold”
- Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Tuesday. A number of other equities research analysts have also recently commented on XENE. Royal Bank of Canada cut their target price on Xenon Pharmaceuticals from $58.00 to […] - 2025-05-15 02:16:49
- Raymond James Financial Inc. Invests $797,000 in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
- Raymond James Financial Inc. purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 20,331 shares of the biopharmaceutical company’s stock, valued at approximately $797,000. A number of […] - 2025-05-07 04:38:48
- William Blair Reiterates Outperform Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
- Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at William Blair in a note issued to investors on Monday,RTT News reports. XENE has been the topic of several other reports. The Goldman Sachs Group dropped their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set […] - 2025-05-07 02:22:49
- Xenon Pharmaceuticals (NASDAQ:XENE) Cut to “Sell” at StockNews.com
- StockNews.com downgraded shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) from a hold rating to a sell rating in a report released on Friday morning. XENE has been the topic of several other reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a […] - 2025-05-05 02:28:52
- Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors acquired 4,063 put options on the company. This is an increase of approximately 2,362% compared to the average daily volume of 165 put options. Xenon Pharmaceuticals Stock Performance XENE opened at $38.20 on Thursday. The […] - 2025-05-01 04:46:54
- Guggenheim Capital LLC Decreases Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
- Guggenheim Capital LLC lowered its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 41.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,177 shares of the biopharmaceutical company’s stock after selling 4,452 shares during the quarter. Guggenheim Capital LLC’s holdings in […] - 2025-04-29 05:30:55
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $56.78 Consensus PT from Analysts
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has been given a consensus recommendation of “Buy” by the ten analysts that are presently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock […] - 2025-04-29 03:10:55
- Invesco Ltd. Cuts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
- Invesco Ltd. cut its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,554 shares of the biopharmaceutical company’s stock after selling 6,268 shares during the quarter. […] - 2025-04-24 05:00:53
- Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the target of unusually large options trading on Wednesday. Traders acquired 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Wall Street Analyst Weigh In A number of analysts have commented on the […] - 2025-04-17 04:41:09
- Xenon Pharmaceuticals (NASDAQ:XENE) Rating Lowered to Sell at StockNews.com
- Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Wednesday. Several other equities research analysts have also recently commented on XENE. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, […] - 2025-04-16 03:10:56
- Trexquant Investment LP Has $447,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
- Trexquant Investment LP trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 32.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,397 shares of the biopharmaceutical company’s stock after selling 5,510 shares during the period. Trexquant […] - 2025-04-13 05:31:04
iShares MSCI World Small Cap UCITS ETF USD (Acc) XENE holdings
| Date | Number of XENE Shares Held | Base Market Value of XENE Shares | Local Market Value of XENE Shares | Change in XENE Shares Held | Change in XENE Base Value | Current Price per XENE Share Held | Previous Price per XENE Share Held |
|---|
| 2025-11-27 (Thursday) | 51,372 | USD 2,285,540 | USD 2,285,540 | 0 | USD 0 | USD 44.49 | USD 44.49 |
| 2025-11-26 (Wednesday) | 51,372 | USD 2,285,540 | USD 2,285,540 | -97 | USD 23,992 | USD 44.49 | USD 43.94 |
| 2025-11-25 (Tuesday) | 51,469 | USD 2,261,548 | USD 2,261,548 | 0 | USD 97,277 | USD 43.94 | USD 42.05 |
| 2025-11-24 (Monday) | 51,469 | USD 2,164,271 | USD 2,164,271 | 0 | USD 45,807 | USD 42.05 | USD 41.16 |
| 2025-11-21 (Friday) | 51,469 | USD 2,118,464 | USD 2,118,464 | 0 | USD 45,807 | USD 41.16 | USD 40.27 |
| 2025-11-20 (Thursday) | 51,469 | USD 2,072,657 | USD 2,072,657 | 306 | USD -7,119 | USD 40.27 | USD 40.65 |
| 2025-11-19 (Wednesday) | 51,163 | USD 2,079,776 | USD 2,079,776 | 3,060 | USD 126,313 | USD 40.65 | USD 40.61 |
| 2025-11-18 (Tuesday) | 48,103 | USD 1,953,463 | USD 1,953,463 | 0 | USD 0 | USD 40.61 | USD 40.61 |
| 2025-11-17 (Monday) | 48,103 | USD 1,953,463 | USD 1,953,463 | 0 | USD -7,215 | USD 40.61 | USD 40.76 |
| 2025-11-14 (Friday) | 48,103 | USD 1,960,678 | USD 1,960,678 | -388 | USD 19,098 | USD 40.76 | USD 40.04 |
| 2025-11-13 (Thursday) | 48,491 | USD 1,941,580 | USD 1,941,580 | 0 | USD 17,457 | USD 40.04 | USD 39.68 |
| 2025-11-12 (Wednesday) | 48,491 | USD 1,924,123 | USD 1,924,123 | 0 | USD -11,638 | USD 39.68 | USD 39.92 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of XENE by Blackrock for IE00BF4RFH31
Show aggregate share trades of XENE| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-11-26 | SELL | -97 | | | 44.490* | | 36.82 Profit of 3,571 on sale |
| 2025-11-20 | BUY | 306 | | | 40.270* | | 36.72 |
| 2025-11-19 | BUY | 3,060 | | | 40.650* | | 36.70 |
| 2025-11-14 | SELL | -388 | | | 40.760* | | 36.64 Profit of 14,216 on sale |
| 2025-10-29 | BUY | 194 | 42.300 | 42.765 | 42.718 | USD 8,287 | 36.42 |
| 2025-10-21 | BUY | 388 | 43.040 | 43.840 | 43.760 | USD 16,979 | 36.24 |
| 2025-10-07 | BUY | 194 | 39.160 | 39.650 | 39.601 | USD 7,683 | 36.15 |
| 2025-09-08 | SELL | -388 | 38.190 | 38.910 | 38.838 | USD -15,069 | 36.02 Loss of -1,095 on sale |
| 2025-08-15 | BUY | 194 | 38.230 | 38.500 | 38.473 | USD 7,464 | 36.00 |
| 2025-08-07 | BUY | 582 | 33.630 | 34.633 | 34.533 | USD 20,098 | 36.01 |
| 2025-07-29 | BUY | 194 | 30.870 | 31.560 | 31.491 | USD 6,109 | 36.14 |
| 2025-07-14 | BUY | 392 | 32.600 | 33.233 | 33.170 | USD 13,003 | 36.35 |
| 2025-06-30 | BUY | 392 | 31.300 | 32.570 | 32.443 | USD 12,718 | 36.54 |
| 2025-06-25 | BUY | 582 | 31.760 | 32.370 | 32.309 | USD 18,804 | 36.63 |
| 2025-06-20 | SELL | -98 | 32.050 | 32.720 | 32.653 | USD -3,200 | 36.73 Profit of 400 on sale |
| 2025-06-12 | SELL | -784 | 32.800 | 33.320 | 33.268 | USD -26,082 | 36.94 Profit of 2,875 on sale |
| 2025-06-02 | BUY | 297 | 30.070 | 30.370 | 30.340 | USD 9,011 | 37.30 |
| 2025-05-28 | BUY | 196 | 28.490 | 29.675 | 29.556 | USD 5,793 | 37.51 |
| 2025-05-14 | BUY | 97 | 29.740 | 30.220 | 30.172 | USD 2,927 | 38.16 |
| 2025-05-13 | BUY | 194 | 29.600 | 33.000 | 32.660 | USD 6,336 | 38.23 |
| 2025-05-07 | BUY | 291 | 35.330 | 36.220 | 36.131 | USD 10,514 | 38.34 |
| 2025-04-28 | BUY | 97 | 37.840 | 38.550 | 38.479 | USD 3,732 | 38.38 |
| 2025-04-16 | BUY | 1,274 | 33.780 | 33.780 | 33.780 | USD 43,036 | 38.58 |
| 2025-04-14 | BUY | 196 | 33.440 | 33.720 | 33.692 | USD 6,604 | 38.70 |
| 2025-04-08 | SELL | -196 | 28.230 | 31.430 | 31.110 | USD -6,098 | 39.07 Profit of 1,561 on sale |
| 2025-04-04 | SELL | -198 | 29.400 | 30.760 | 30.624 | USD -6,064 | 39.29 Profit of 1,715 on sale |
| 2025-03-28 | BUY | 980 | 34.260 | 34.800 | 34.746 | USD 34,051 | 39.62 |
| 2025-03-12 | SELL | -196 | 35.480 | 35.950 | 35.903 | USD -7,037 | 40.39 Profit of 880 on sale |
| 2025-03-04 | SELL | -196 | 36.020 | 37.270 | 37.145 | USD -7,280 | 40.76 Profit of 708 on sale |
| 2025-02-28 | SELL | -5,107 | 37.020 | 37.670 | 37.605 | USD -192,049 | 40.90 Profit of 16,809 on sale |
| 2025-02-26 | SELL | -436 | 39.100 | 40.000 | 39.910 | USD -17,401 | 40.97 Profit of 462 on sale |
| 2025-02-13 | BUY | 110 | 39.260 | 39.840 | 39.782 | USD 4,376 | 41.34 |
| 2025-02-12 | BUY | 440 | 39.500 | 39.520 | 39.518 | USD 17,388 | 41.38 |
| 2025-01-27 | BUY | 109 | 40.110 | 41.240 | 41.127 | USD 4,483 | 41.89 |
| 2025-01-23 | BUY | 109 | 39.980 | 40.280 | 40.250 | USD 4,387 | 42.00 |
| 2024-12-09 | BUY | 3,960 | 42.050 | 43.380 | 43.247 | USD 171,258 | 42.18 |
| 2024-12-04 | BUY | 218 | 42.340 | 43.000 | 42.934 | USD 9,360 | 42.18 |
| 2024-12-03 | BUY | 327 | 42.000 | 42.600 | 42.540 | USD 13,911 | 42.19 |
| 2024-11-19 | BUY | 660 | 38.850 | 39.130 | 39.102 | USD 25,807 | 42.60 |
| 2024-11-18 | BUY | 220 | 38.310 | 40.040 | 39.867 | USD 8,771 | 42.86 |
| 2024-11-12 | BUY | 436 | 43.390 | 44.500 | 44.389 | USD 19,354 | 42.82 |
| 2024-11-11 | BUY | 109 | 44.070 | 45.450 | 45.312 | USD 4,939 | 42.74 |
| 2024-11-07 | BUY | 545 | 45.740 | 45.820 | 45.812 | USD 24,968 | 42.34 |
| 2024-10-23 | BUY | 216 | 41.660 | 42.660 | 42.560 | USD 9,193 | 43.48 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of XENE
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 94,121 | 0 | 116,537 | 80.8% |
| 2025-09-18 | 166,160 | 0 | 196,562 | 84.5% |
| 2025-09-17 | 153,610 | 0 | 353,729 | 43.4% |
| 2025-09-16 | 127,586 | 0 | 236,754 | 53.9% |
| 2025-09-15 | 95,792 | 14 | 178,183 | 53.8% |
| 2025-09-12 | 70,043 | 0 | 198,178 | 35.3% |
| 2025-09-11 | 96,068 | 0 | 181,331 | 53.0% |
| 2025-09-10 | 122,078 | 0 | 189,803 | 64.3% |
| 2025-09-09 | 90,865 | 0 | 283,996 | 32.0% |
| 2025-09-08 | 232,027 | 100 | 301,530 | 76.9% |
| 2025-09-05 | 156,900 | 0 | 238,492 | 65.8% |
| 2025-09-04 | 166,307 | 0 | 271,514 | 61.3% |
| 2025-09-03 | 157,066 | 0 | 271,074 | 57.9% |
| 2025-09-02 | 81,739 | 0 | 248,041 | 33.0% |
| 2025-08-29 | 152,207 | 0 | 232,164 | 65.6% |
| 2025-08-28 | 61,706 | 0 | 157,013 | 39.3% |
| 2025-08-27 | 83,791 | 0 | 140,984 | 59.4% |
| 2025-08-26 | 138,841 | 12 | 233,008 | 59.6% |
| 2025-08-25 | 90,644 | 0 | 153,535 | 59.0% |
| 2025-08-22 | 241,402 | 0 | 680,379 | 35.5% |
| 2025-08-21 | 240,881 | 0 | 412,449 | 58.4% |
| 2025-08-20 | 121,216 | 0 | 174,820 | 69.3% |
| 2025-08-19 | 140,464 | 0 | 214,610 | 65.5% |
| 2025-08-18 | 180,294 | 0 | 305,703 | 59.0% |
| 2025-08-15 | 160,339 | 2,610 | 215,321 | 74.5% |
| 2025-08-14 | 238,992 | 0 | 350,208 | 68.2% |
| 2025-08-13 | 372,443 | 0 | 746,027 | 49.9% |
| 2025-08-12 | 467,887 | 0 | 696,577 | 67.2% |
| 2025-08-11 | 270,332 | 55 | 374,372 | 72.2% |
| 2025-08-08 | 242,928 | 90 | 362,883 | 66.9% |
| 2025-08-07 | 167,847 | 368 | 222,326 | 75.5% |
| 2025-08-06 | 192,634 | 0 | 261,533 | 73.7% |
| 2025-08-05 | 641,973 | 50 | 1,267,219 | 50.7% |
| 2025-08-04 | 456,814 | 0 | 843,073 | 54.2% |
| 2025-08-01 | 190,981 | 5,139 | 229,705 | 83.1% |
| 2025-07-31 | 195,002 | 781 | 223,443 | 87.3% |
| 2025-07-30 | 154,824 | 900 | 252,506 | 61.3% |
| 2025-07-29 | 243,814 | 1,587 | 303,064 | 80.4% |
| 2025-07-28 | 320,579 | 0 | 650,128 | 49.3% |
| 2025-07-25 | 214,658 | 100 | 341,862 | 62.8% |
| 2025-07-24 | 138,436 | 0 | 204,720 | 67.6% |
| 2025-07-23 | 119,232 | 0 | 205,068 | 58.1% |
| 2025-07-22 | 103,454 | 0 | 214,734 | 48.2% |
| 2025-07-21 | 212,989 | 0 | 246,308 | 86.5% |
| 2025-07-18 | 176,030 | 0 | 205,045 | 85.8% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.